Forward-looking statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Market growth rates used in this presentation are estimates based on Company and third-party industry research. The reported number of physicians (600K) and patients in Epic's network (250M) were provided by Epic.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP to non-GAAP financial results is provided under the investor section of Myriad’s corporate website at www.myriad.com.
Our vision and opportunity:
Better health through genetic insights

Paul J. Diaz, President and CEO
Moving from transformation to expansion and growth

Revealing the power of genetic insights – for everyone

Mission
We advance health and well-being for all, empowering every individual by revealing the answers inside each of us.

Vision
As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health, and enable healthcare providers to better detect, treat and prevent disease.

Health. Illuminated.
Serving a more patient-centric healthcare system

Fast-growing

Personalized

Data-driven

1.3M Myriad Genetics tests/year

60,000 active ordering physicians

~10%+ YoY market growth across Mental Health, Women’s Health, Oncology

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com
A trusted partner with specialized expertise

Driving value by better serving patients and customers
Listening to patient and customer needs

Making it easier to do business with us
Collaboration
Partnering with healthcare innovators

Creating a more patient-centric healthcare system
Inclusion
Making genetic testing more accessible and affordable

$49M of financial assistance provided to 86,000+ eligible patients in 2021.

95% of payers cover Myriad hereditary cancer testing

New point of care financial accessibility tools and payment programs

MyRisk™ Hereditary Cancer Test

RiskScore® for all ancestries

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com
Simplification and ease of use

Improving the customer experience

Customer-centric, tech-enabled tools to reduce complexity and cost

$50M investment in point-of-care technology and digital tools

EMR integration
600K providers will be able to order Myriad test for 250M patients in Epic network*

* Integration with Epic expected to go live later this year
Innovation
Elevating our products, investing in our labs

Innovative new product pipeline and state-of-the-art labs

$80M investment in state-of-the-art Labs of the Future

$25M+ annual incremental investment in research and development
Up next

**Executing to win**
Expanding commercial sales and marketing capabilities to increase access to genetic testing and drive growth

**Engaging our team**
Driving service and operational excellence

**Enhancing core lab capabilities**
Supporting growth, productivity, and innovation | Lab of the Future

**Tech-enabled commercial capabilities**
Improving the customer experience and driving growth

**What’s next**
Innovating and elevating our product pipeline

**Delivering value**
Long-term growth and profitability

Mark Verratti
Chief Commercial Officer

Nicole Lambert
Chief Operating Officer

Kevin Haas, Ph.D.
Chief Technology Officer

Dale Muzzey, Ph.D.
Chief Scientific Officer

Bryan Riggsbee
Chief Financial Officer